Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of ENZO BIOCHEM INC from 31 Jul 2016 to 30 Apr 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
ENZO BIOCHEM INC quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD history and change rate from 31 Jul 2016 to 30 Apr 2025.
  • ENZO BIOCHEM INC Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 30 Apr 2025 was $36,693,000, a 36% decline year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

ENZO BIOCHEM INC Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $36,693,000 -$20,463,000 -36% 30 Apr 2025 10-Q 16 Jun 2025 2025 Q3
Q4 2024 $40,297,000 -$19,944,000 -33% 31 Jan 2025 10-Q 17 Mar 2025 2025 Q2
Q3 2024 $47,735,000 -$21,472,000 -31% 31 Oct 2024 10-Q 16 Dec 2024 2025 Q1
Q2 2024 $52,371,000 -$31,002,000 -37% 31 Jul 2024 10-Q 16 Jun 2025 2025 Q3
Q1 2024 $57,156,000 +$53,524,000 +1474% 30 Apr 2024 10-Q 16 Jun 2025 2025 Q3
Q4 2023 $60,241,000 +$54,187,000 +895% 31 Jan 2024 10-Q 17 Mar 2025 2025 Q2
Q3 2023 $69,207,000 +$56,072,000 +427% 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1
Q2 2023 $83,373,000 +$60,770,000 +269% 31 Jul 2023 10-Q 16 Jun 2025 2025 Q3
Q1 2023 $3,632,000 -$28,498,000 -89% 30 Apr 2023 10-Q 13 Jun 2024 2024 Q3
Q4 2022 $6,054,000 +$895,000 +17% 31 Jan 2023 10-Q 13 Mar 2024 2024 Q2
Q3 2022 $13,135,000 +$6,029,000 +85% 31 Oct 2022 10-Q 15 Dec 2023 2024 Q1
Q2 2022 $22,603,000 +$8,329,000 +58% 31 Jul 2022 10-K 29 Oct 2024 2024 FY
Q1 2022 $32,130,000 +$16,291,000 +103% 30 Apr 2022 10-Q 14 Jun 2023 2023 Q3
Q4 2021 $5,159,000 -$40,127,000 -89% 31 Jan 2022 10-Q 20 Mar 2023 2023 Q2
Q3 2021 $7,106,000 -$39,558,000 -85% 31 Oct 2021 10-Q 12 Dec 2022 2023 Q1
Q2 2021 $14,274,000 -$34,341,000 -71% 31 Jul 2021 10-K 03 Nov 2023 2023 FY
Q1 2021 $15,839,000 -$39,318,000 -71% 30 Apr 2021 10-Q 09 Jun 2022 2022 Q3
Q4 2020 $45,286,000 -$6,966,000 -13% 31 Jan 2021 10-Q 14 Mar 2022 2022 Q2
Q3 2020 $46,664,000 -$10,979,000 -19% 31 Oct 2020 10-Q 15 Dec 2021 2022 Q1
Q2 2020 $48,615,000 -$12,281,000 -20% 31 Jul 2020 10-K 14 Oct 2022 2022 FY
Q1 2020 $55,157,000 -$9,645,000 -15% 30 Apr 2020 10-Q 11 Jun 2021 2021 Q3
Q4 2019 $52,252,000 +$9,524,000 +22% 31 Jan 2020 10-Q 16 Mar 2021 2021 Q2
Q3 2019 $57,643,000 +$4,866,000 +9.2% 31 Oct 2019 10-Q 11 Dec 2020 2021 Q1
Q2 2019 $60,896,000 +$855,000 +1.4% 31 Jul 2019 10-K 14 Oct 2022 2022 FY
Q1 2019 $64,802,000 +$2,246,000 +3.6% 30 Apr 2019 10-Q 09 Jun 2020 2020 Q3
Q4 2018 $42,728,000 -$21,740,000 -34% 31 Jan 2019 10-Q 06 Mar 2020 2020 Q2
Q3 2018 $52,777,000 31 Oct 2018 10-Q 10 Dec 2019 2019 Q1
Q2 2018 $60,041,000 -$4,126,000 -6.4% 31 Jul 2018 10-K 12 Oct 2021 2021 FY
Q1 2018 $62,556,000 30 Apr 2018 10-Q 10 Jun 2019 2019 Q3
Q4 2017 $64,468,000 31 Jan 2018 10-Q 11 Mar 2019 2019 Q2
Q2 2017 $64,167,000 -$3,610,000 -5.3% 31 Jul 2017 10-K 19 Oct 2020 2020 FY
Q2 2016 $67,777,000 31 Jul 2016 10-K 15 Oct 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.